--- title: "West Pharmaceutical Services (NYSE:WST) to Buyback $1.00 billion in Outstanding Shares" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/276193221.md" description: "West Pharmaceutical Services (NYSE:WST) has announced a $1.00 billion share buyback program, allowing the company to repurchase up to 5.6% of its outstanding shares. This decision reflects the board's belief that the stock is undervalued. The company's stock recently traded down 2.9% to $243.27, with a market cap of $17.50 billion. West reported a quarterly EPS of $2.04, exceeding estimates, and has set FY 2026 guidance at 7.850-8.200 EPS. Analysts have mixed ratings on the stock, with an average target price of $314.56." datetime: "2026-02-18T03:13:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276193221.md) - [en](https://longbridge.com/en/news/276193221.md) - [zh-HK](https://longbridge.com/zh-HK/news/276193221.md) --- > 支持的语言: [English](https://longbridge.com/en/news/276193221.md) | [繁體中文](https://longbridge.com/zh-HK/news/276193221.md) # West Pharmaceutical Services (NYSE:WST) to Buyback $1.00 billion in Outstanding Shares West Pharmaceutical Services (NYSE:WST - Get Free Report) announced that its board has initiated a stock repurchase plan on Tuesday, February 17th, RTT News reports. The company plans to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued. ## West Pharmaceutical Services Stock Down 2.9% - 3 Dividend Champions with room for dividend growth Shares of NYSE WST traded down $7.22 during mid-day trading on Tuesday, reaching $243.27. 969,895 shares of the company were exchanged, compared to its average volume of 1,265,581. West Pharmaceutical Services has a 1 year low of $187.43 and a 1 year high of $322.34. The firm has a 50-day moving average of $260.12 and a 200 day moving average of $261.81. The stock has a market cap of $17.50 billion, a price-to-earnings ratio of 35.83, a P/E/G ratio of 3.27 and a beta of 1.18. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06. West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The business had revenue of $805.00 million during the quarter, compared to the consensus estimate of $795.70 million. During the same period in the previous year, the company posted $1.82 earnings per share. The firm's revenue was up 7.5% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, research analysts expect that West Pharmaceutical Services will post 6.62 earnings per share for the current year. ## West Pharmaceutical Services Announces Dividend - What Factors Will Drive S&P 500 Performance This Year? The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th were paid a $0.22 dividend. The ex-dividend date was Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services's dividend payout ratio (DPR) is 12.96%. ## Wall Street Analyst Weigh In Several equities research analysts recently weighed in on the stock. Evercore reduced their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 3rd. Barclays lowered their target price on shares of West Pharmaceutical Services from $325.00 to $265.00 and set an "equal weight" rating for the company in a report on Friday. Weiss Ratings reiterated a "hold (c)" rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Jefferies Financial Group reissued a "buy" rating and issued a $295.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Finally, UBS Group restated a "buy" rating and set a $340.00 target price on shares of West Pharmaceutical Services in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $314.56. - Healthcare Stocks With at Least 30 Years of Dividend Increases **View Our Latest Stock Analysis on WST** ## West Pharmaceutical Services Company Profile Get Free Report) West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations. In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle. ## Read More - Five stocks we like better than West Pharmaceutical Services - Your Bank Account Is No Longer Safe - Nvidia CEO Issues Bold Tesla Call - Buy this Gold Stock Before May 2026 - What a Former CIA Agent Knows About the Coming Collapse - This $15 Stock Could Go Down as the #1 Stock of 2026 _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in West Pharmaceutical Services Right Now? Before you consider West Pharmaceutical Services, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list. While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相关股票 - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-CN/quote/XHE.US.md) - [West Pharmaceutical (WST.US)](https://longbridge.com/zh-CN/quote/WST.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) ## 相关资讯与研究 - [Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD](https://longbridge.com/zh-CN/news/281179756.md) - [MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation | VATE Stock News](https://longbridge.com/zh-CN/news/281183004.md) - [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/zh-CN/news/281240360.md) - [ENDRA Life Sciences Q4 net loss narrows](https://longbridge.com/zh-CN/news/281239377.md) - [Perimeter Posts Record 2025 Revenue and Wins FDA Approval for AI Breast Imaging Device](https://longbridge.com/zh-CN/news/281274047.md)